(Unterschied) ← Nächstältere Version | Aktuelle Version (Unterschied) | Nächstjüngere Version → (Unterschied)
rna polymerase and full rna replication complex includes nsp12, nsp8, nsp7
32321524 2020. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
| 32277040 2020. Structure of the RNA-dependent RNA polymerase from COVID-19 virus
|
32167173 ä. The potential chemical structure of anti?SARS?CoV?2 RNA?dependent RNA polymerase
| 32511245 2020. A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis.
|
| 32438371 2020. Structure of replicating SARS-CoV-2 polymerase.
|
| 32443810 2020. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.
|
32427393 2020. Telomeres and COVID-19.
| 32392072 2020. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.
|
| 32526208 2020. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
|
| 32531208 2020. Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2.
|
32718300 2020. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
32720571 2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.
32720577 2020. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis.
32754651 2020. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.
32805774 2020. RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19.
32948103 2020. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
33027419 2020. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp).
33084512 2020. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations.
33134697 2020. Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections.
33155531 2020. Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach.
33281478 2020. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.
33287144 2020. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge.
C7309803 2020. Azafluorene derivatives as inhibitors of SARS CoV-2 RdRp: Synthesis physicochemical quantum chemical modeling and molecular docking analysis.
32306854 2020. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.
32442424 2020. Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.
32617855 2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
| 32633831 2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.
|
32635935 2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
32660307 2020. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
32692185 2020. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
32727069 2020. A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity.
32743211 2020. Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase.
32752938 2020. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.
32812340 2020. Vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the SARS-CoV-2 virus.
32873176 2020. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses.
32950529 2020. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
33014317 2020. Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil.
33110386 2020. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.
33122171 2020. Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase.
33168456 2020. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
| 33186044 2020. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
|
33195080 2020. Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations.
33200678 2020. Computational investigation for identification of potential phytochemicals and antiviral drugs as potential inhibitors for RNA-dependent RNA polymerase of COVID-19.
33204411 2020. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19.
33281876 2020. Identification of Potential Key Agents for Targeting RNA-Dependent RNA Polymerase of SARS-CoV-2 by Integrated Analysis and Virtual Drug Screening.
33288200 2020. The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.
C7261222 ?. Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach.
C7677616 ?. Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV.
| 32933378 2020. Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach.
|
| 33185784 2020. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
|
